1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Massachusetts >
  6. Novartis Acquires Vedere Bio

M&A Deal Summary

Novartis Acquires Vedere Bio

On October 29, 2020, Novartis acquired life science company Vedere Bio for 150M USD

Acquisition Highlights
  • This is Novartis’ 18th transaction in the Life Science sector.
  • This is Novartis’ 17th largest (disclosed) transaction.
  • This is Novartis’ 19th transaction in the United States.
  • This is Novartis’ 3rd transaction in Massachusetts.

M&A Deal Summary
Date 2020-10-29
Target Vedere Bio
Sector Life Science
Buyer(s) Novartis
Deal Type Add-on Acquisition
Deal Value 150M USD

Target

Vedere Bio

Cambridge, Massachusetts, United States
Vedere Bio, Inc. is a stealth-stage company focused on advancing photoreceptor-protein-based optogenetic therapies that are delivered to the retina intravitreally to restore functional vision. Vedere Bio is based in Cambridge, Massachusetts.

Search 215,058 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Novartis

Basel, Switzerland
Category Company
Founded 1996
Sector Life Science
Employees104,323
Revenue 51.8B USD (2024)
DESCRIPTION
Novartis' corporate campus in Basel, Switzerland.
Novartis' corporate campus in Basel, Switzerland.

Novartis is a healthcare and pharmaceutical enterprise dedicated to advancing medical innovation and enhancing patient well-being. Renowned for its pioneering research and development efforts, Novartis has a comprehensive portfolio encompassing groundbreaking pharmaceuticals, generic medications, biosimilars, and eye care solutions. Novartis was founded in 1996 and is based in Basel, Switzerland.

DEAL STATS #
Overall 23 of 36
Sector: Life Science M&A 18 of 30
Type: Add-on Acquisition M&A Deals 19 of 30
State: Massachusetts M&A 3 of 7
Country: United States M&A 19 of 28
Year: 2020 M&A 2 of 4
Size (of disclosed) 17 of 20
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-04-20 Amblyotech

United States

Amblyotech, Inc. is a digital therapeutics software company, which develops active and passive video therapies to treat amblyopia ("lazy eye"), a debilitating ocular condition that affects 3% of the global population and is a leading cause of monocular blindness. Amblyotech was founded in 2013 and is based in United States.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-12-17 Cadent Theraputics

Cambridge, Massachusetts, United States

Cadent Theraputics, Inc. is a biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders. Cadent combines target specificity, patient selection, drug design and optimization, and novel quantitative endpoints to create first-in-class molecules to treat cognitive and movement disorders. Cadent Theraputics is based in Cambridge, Massachusetts.

Buy $770M
Mergr

Solution for

Product

Company

Legal